Advocates for Human Potential, Inc.

A Bureau of Justice Assistance (BJA) funded program 
provided by
Advocates for Human Potential, Inc. (AHP) in partnership with Treatment Alternatives for Safe Communities (TASC).

Annual RSAT Meeting at the NCJA 2020 Virtual Forum on Criminal Justice


For the second year in a row, RSAT TTA will host its annual meeting in conjuction with the National Criminal Justice Association forum on criminal justice. This year's NCJA forum will be held virtually on December 9-10, 2020, and the RSAT meeting will be held prior to the breakout sessions on Thursday, December 10th at 12pm EST.

Workshop sessions will examine the impact of the pandemic on justice reform policy and what that means moving forward, the future of diversion programs, rural justice issues and lessons learned from COVID-19 both in the United States and internationally. Keynote speaker Dr. Emily Wang from the Health and Justice Lab at Yale University will kick off the conference by weaving together how the health impact of the pandemic is effecting criminal justice policymaking. 

Registration for the NCJA Forum is $150 for NCJA and ICCA members and $200 for non-members. There is NO additional fee for the RSAT meeting. Please register for the RSAT Meeting and NCJA Forum individually.


Register for the 2020 RSAT Annual Meeting 

Register for the NCJA Forum on Criminal Justice

View the NCJA Forum Agenda

NEW RSAT Training Film!

Jail MAT Begins with Immediate Clinical Intake

Promising Practices Guidelines for Residential Substance Abuse Treatment


Jail-Based Medication-Assisted Treatment

Reentry Strategies to Reduce Recidivism and Sustain Recovery

Overdose Risk Reduction and Relapse Prevention for RSAT Programs

Role of Corrections Officers in Jail/Prison Substance Use Disorder Treatment Programs

Integrated Substance Abuse Treatment for Clients with 

Co-Occurring Mental Health Disorders

Updated Fed Regulations for Methadone & Buprenorphine

The federal government has now made it easier for persons to access methadone and buprenorphine. Refer to the DEA website for details.

  • Methadone clinics may now give stable patients a four week supply to take home and two weeks for less stable patients if the clinics believe this can be done safely.
  • In some circumstances, methadone may be delivered to quarantined patients by authorized personnel.
  • Opioid Treatment Programs (OTPs) can dispense and DATA-waivered practitioners can now prescribe buprenorphine to new patients with OUD for maintenance or detoxification treatment following an evaluation by telephone. There is no need for an in-person or telemedicine evaluation.
  • This should allow jails and prisons to connect persons requesting prescriptions for buprenorphine with DATA-waivered practitioners without requiring those practitioners to be on-site at a correctional facility.
  • These new regulations will remain in effect during the course of the pandemic according to the DEA and SAMHSA, unless otherwise specified.

Note: HIPAA violations will not be enforced during epidemic. On March 17, 2020, the Office of Civil Rights announced, effective immediately, that it will waive potential penalties for HIPAA violations against health care providers using non-HIPAA compliant communication technologies (i.e. FaceTime or Skype) during the COVID-19 pandemic.

You can find detailed information on the DEA policy and SAMHSA website.

Other National Correctional MAT Manuals and Resources

Pharmacotherapy plus CBT should be best practice for addiction treatment, data show
ASAM National Practice Guidelines for the Treatment of OUD-2020
Medication-Assisted Treatment for Opioid Use Disorder in Jails and Prisons: A Planning and Implementation Toolkit
The National Sheriffs' Association Supports the Use of FDA Approved and Evidence-Based Medication-Assisted Treatment (MAT) for Opioid Use Disorder in County Jails
A New Year’s Gift: CMS implements Medicare as an additional payor for MAT services from Opioid Treatment Programs
Medication-assisted Treatment Inside Correctional Facilities
Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings
Colorado Jail Based Behavioral Health Services
Kentucky DOC Substance Abuse Medication Assisted Treatment Protocol
Rhode Island Vivitrol Manual
Rhode Island Suboxone SOP
Rhode Island Distribution of Suboxone Protocol
Massachusetts Department of Correction Medication Assisted Treatment Re-Entry Initiative (MATRI) Clinical Guidelines
Vermont MAT for Inmates: Work Group Evaluation Report and Recommendations
New Hampshire DOC MAT and Naltrexone Oral Augmentation Clinical Guidelines
Department of Vermont Health Access, Managed Care Entity, Vermont Buprenorphine Clinical Practice Guidelines, August 2015

Correctional MAT Videos

SAMHSA Video: Benefits and Cost Savings of MAT
Services in a Correctional Setting

This video features presentations from Jon Berge, SAMHSA, Mark Parrino, American Association for the Treatment of Opioid Dependence, Andrew Klein, RSAT TTA and Advocates for Human Potential, Kathleen Maurer, Connecticut DOC, and Kevin Pangburn, Kentucky DOC.

Montgomery County Corrections

Montgomery County, Maryland Department of Correction and Rehabilitation
video on that institution’s MAT Program

Massachusetts Department of Corrections

Brief descriptions of some Prison and Jail MAT Programs

Kentucky Prison, Massachusetts Prison, Philadelphia Jail, Rhode Island Prison,
West Virginia Prison, Wisconsin, Sacramento Jail, New Haven and Bridgeport Jails (Administered by state DOC), Kenton County, Kentucky Jail, Montgomery County, Maryland Jail, Barnstable County, Massachusetts Jail, Middlesex County, New York City Jail, and Salt Lake City Jail

Medication Assisted Treatment Programs In Vermont State Corectional Facilities

This report reviews state correctional MAT programs in VT, MA, NH, MO, RI & KY, and includes the latest cost and recidivism data from most of them.


Report on New Hampshire DOC MAT in Custody
Naltrexone Program

RSAT Program Spotlight

A brief glimpse of some great RSAT programs

For the last six months, RSAT TTA has been reaching out to all currently funded jail and prison RSAT programs across the county and US territories to get the latest on what and how they are doing in these difficult times. Eventually, this section will include every program funded each year, but we don't want to wait to share with you descriptions of the exciting and diverse programs surveyed so far. Please check back soon for links to compendiums, including descriptions and contacts, of RSAT jail and prison programs by state.

If your program is not yet included, we will get to you. You can assist by contacting Steve Keller at with your contact information and we will put you next on the list! Keep up your terrific work.

Our RSAT TTA website will also be displaying an interactive Google map of all RSAT-funded programs around the country. You will be able to search by program type, drug treatment offered and by special populations served. We hope this will serve as an informational networking tool for RSAT program directors, staff and grant administrators.

  • Should Benzodiazepines and Opioids Be Used Concurrently?

    This examines the use of benzodiazepines for persons with OUD. The conclusion it is not safe, but there are exceptions.

  • Heavy Drinking is Killing Women in Record Numbers, and Experts Fear a Coronavirus-Related Spike

    While alcohol-related deaths have risen by 51% from 1999 to 2017, there has been an 81% increase seen in women.

  • Treatment of Stimulant Use Disorders

    SAMHSA's evidenced-based guide on treatment of stimulant use disorders published June 2020.

  • Significant Changes in Drug Use During the Pandemic

    Since COVID-19 pandemic fentanyl and methamphetamine use is rising, heroin and cocaine falling.

  • Buprenorphine, Suboxone and the Treatment of Opioid Use Disorder (OUD) in 2020

    This article focuses on buprenorphine in the treatment of opioid use disorder and offers a comprehensive overview of all forms of the medication. It provides updated links to information and research including phases of treatment, diversion and abuse of buprenorphine, length of time in treatment and detoxification, and barriers and stigma associated to access and treatment.

  • Use of Codeine, Oxycodone, and Other Opioids: Information for Employees

    While making clear that current illegal drug use is not a covered disability, the US Equal Employment Opportunity Commission document clarifies that individuals who are lawfully using opioid medication, are in treatment for opioid addiction and are receiving Medication Assisted Treatment (MAT), or have recovered from their addiction, are protected from disability discrimination. In addition, the document answers questions about reasonable accommodations that may be available to employees who currently legally use opioids, as well as what to do if an employer has concerns about the employee’s ability to safely perform his or her job.

  • AMA: Prescription opioids eclipsed by illicit drugs in US overdose epidemic

    Prescribed opioids are down, use of naloxone and PDMPs are up, but so is illicit opioid use, resulting in increasing OD deaths.

  • Methadone Patients' Data Poised to Be Entered Into PDMPs

    SAMHSA now allows opioid treatment programs (OTPs) to put patient information into prescription drug monitoring programs (PDMPs). It will be up to each state whether this will be done. Persons on methadone maintenance should be alerted to ask if their data is being entered.

  • Leaving Jail, Addicts Face a Growing Opioid Crisis During a Pandemic

    Describes the added challenges facing persons with substance use disorders upon release.

  • AMA report shows overdose epidemic evolving, becoming deadlier

    Between 2015 and 2019, fentanyl OD deaths increased from 5,766 to 36,509, stimulants, like Methamphetamine, from 4,402 to 16,279, cocaine from 5,496 to 15,974 and heroin from 10,788 to 14,079. Prescription opioid ODs decreased from 12,269 to 11,904.

  • Expanded access to treatment in prisons can reduce overdose deaths by more than 31%, study finds

    Based on the results of the MAT program in Rhode Island’s unified correctional system, study finds providing inmates and detainees with naltrexone, methadone or buprenorphine reduces post release OD deaths, especially for those previously incarcerated.

  • Beneath Tragic New US Overdose Figures, There Are Wide Regional Variations

    ODs were up 4.9% in 2019. This article describes regional differences and theorizes that harm reduction strategies may account for them.

  • New Peak of 71k US Overdose Deaths in 2019 Dashes Hopes

    Lest we forget, nearly 71,000 died of drug overdoses last year setting a new record that predates the COVID-19 crisis. The increase is attributed to fentanyl which accounted for more than half of the deaths according to the CDC. ODs went up in more than 30 states. A rare bright spot was declining OD rates in northeast credited to expanded treatment. We would also add active prison and jail medication-assisted treatment enrollments pioneered by the these states’ RSAT programs!

  • Depot Antipsychotic Delays Hospitalization in Early-Stage Schizophrenia

    New research suggests that long acting injectable antipsychotic medication typically reserved for chronic illness should be considered earlier to avoid lapses in taking medication and need for hospitalization.

  • Treatment of Stimulant Use Disorders

    The use of stimulants, Cocaine and Methamphetamine, is way up, including causing 40% of overdose deaths in 2018. This SAMHSA guide identifies evidence-based treatment, finding strong evidence for motivational interviewing, contingency management, community reinforcement approach, and cognitive behavioral therapy. The guide includes practice resources for each of these treatment approaches and examples and resources for evaluation and quality improvements.

  • Resurgent Methamphetamine use at Treatment Admission in the United States

    Methamphetamine use has been on the rise and is linked to the increase in opioid use. By 2017, 50.4% of methamphetamine overdose deaths involved opioids, suggesting that the rise in methamphetamine-related harms is linked to the ongoing opioid overdose epidemic in the United States.

  • Addicts at High Risk of Contracting Coronavirus

    Homeless, those sleeping in crowded shelters or people with other health conditions — such as hepatitis C, HIV or lung disease — are high risk, said Dr. Daniel Solomon, an infectious disease physician who works at the Brigham Health Bridge Clinic for patients with substance use disorders. For recovering addicts, anxiety about COVID-19 can have a “triggering effect” that can lead to relapse, said James McKowen, a psychologist and clinical director of the Addiction Recovery Management Service at Massachusetts General Hospital, which is moving toward treatment via telemedicine, phone calls and group-based video conferencing to reduce the risk of transmission.

  • SAMHSA Letter to Mental Health Commissioners

    ALERT! SAMHSA clarified that state Community Mental Health Services Block Grants (MHBG) can be used for the care and treatment of incarcerated persons with serious mental illness in prison and jail. RSAT programs serving persons with co-occurring mental illness might qualified for this funding.

  • Naloxone Videos You Can Use

    Here are some helpful videos on Naloxone administration. The first is for Law Enforcement Roll Call, the next is Instructions for Administering NARCAN, and the last is whole series of short videos on Naloxone Training & Education.

  • Promising Practices Archive


Additional RSAT Guides & References

Introduction to Trauma and Trauma-Informed Approaches for RSAT Staff

Preventing, Detecting and Treating HIV/AIDS and Viral Hepatitis: Health Promotion and Risk/Harm Reduction in Substance Abuse Treatment

A Comprehensive Listing of What States Cover for Substance Use Disorder, including Medications

New Manual on
Health Literacy

Once they obtain health coverage, RSAT participants need to maximize the benefits offered in terms of preventive and primary care to promote both better physical and behavioral health.

Recent Medication-Assisted Treatment Studies Relevant to Corrections

"A Rehab Jail for Heroin Addicts" in Franklin County Massachusetts

Franklin County and the Greenfield, Massachusetts community addresses the opioid crisis with an innovative approach to treatment. The Franklin County Jail is one of the only corrections facilities in the country offering suboxone to its clients.

RSAT Jail Program Tour

What Inmates Tell us About RSAT

Participate in our forum!

We know MAT is recommended and is part of the US Justice Department’s RSAT Promising Practices Guidelines, but by the time inmates are referred to our RSAT program, they have already gone through withdrawal, mostly for opioids, although often mixed with other drugs. It seems counter productive to then get them back on drugs. Isn’t that a backwards step?